Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease

Arthritis and Rheumatology

Volumn 66, Issue 7, 2014, Pages 1900-1908

  Volkmann, Elizabeth R ^a   Saggar, Rajeev ^b   Khanna, Dinesh ^c   Torres, Bryant ^d   Flora, Arjan ^e   Yoder, Lynne ^a   Clements, Philip J ^a   Elashoff, Robert M ^a   Ross, David J ^a   Agrawal, Harsh ^f   Borazan, Nabeel ^a   Furst, Daniel E ^a   Saggar, Rajan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d EMORY UNIVERSITY   (United States)

^e ST VINCENT MERCY MEDICAL CENTER   (United States)

^f UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

ADULT; AGED; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHODIESTERASE 5 INHIBITORS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY WEDGE PRESSURE; RECEPTORS, ENDOTHELIN; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; VASCULAR RESISTANCE;

EID: 84903449602     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38623     Document Type: Article

References (28)

1. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-30.
2. Hassoun PM, Shafiq M,. Tackling the challenges of systemic sclerosis-associated pulmonary hypertension: one step forward [editorial]. Arthritis Rheum 2013; 65: 2240-2.
3. O'Callaghan DS, Humbert M,. A critical analysis of survival in pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 218-22.
4. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-7.
5. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-77.
6. Le Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011; 63: 2456-64.
7. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-94.
8. Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, Bonderman D, Schemper M, Klepetko W, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant 2012; 31: 735-43.
9. LeRoy EC, Medsger TA Jr., Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
10. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-54.
11. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
12. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 2009; 36: 2244-9.
13. Lefevre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 2013; 65: 2412-23.
14. Farber HW, Miller DP, Meltzer LA, McGoon MD,. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant 2013; 32: 1114-22.
15. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-619.
16. Delcroix M, Spaas K, Quarck R,. Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy. Eur Respir Rev 2009; 18: 253-9.
17. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
18. Launay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc LJ, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011; 140: 1016-24.
19. Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM,. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 2011; 30: 982-9.
20. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 425-34.
21. Montani D, Jais X, Price LC, Achouh L, Degano B, Mercier O, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009; 34: 1348-56.
22. Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38: 893-902.
23. Colombat M, Mal H, Groussard O, Capron F, Thabut G, Jebrak G, et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007; 38: 60-5.
24. Badagliacca R, Pezzuto B, Poscia R, Mancone M, Papa S, Marcon S, et al. Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. J Heart Lung Transplant 2012; 31: 364-72.
25. Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70: 1788-92.
26. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72: 1940-6.
27. Steen VD, Conte C, Owens GR, Medsger TA Jr., Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-9.
28. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155-60.